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Abstract
Background. This study provides a summary of the 2008
ERA–EDTA Registry Report (this report is available at
www.era-edta-reg.org).
Methods. The data on renal replacement therapy (RRT)
were available from 55 national and regional registries in
30 countries in Europe and bordering the Mediterranean
Sea. Datasets with individual patient data were received
from 36 registries, whereas 19 registries contributed data
in aggregated form. We presented incidence and preva-
lence of RRT, and transplant rates. Survival analysis was
solely based on individual patient records.
Results. In 2008, the overall incidence rate of RRT for
end-stage renal disease (ESRD) among all registries re-
porting to the ERA–EDTA Registry was 122 per million
population (pmp), and the prevalence was 644 pmp. Inci-
dence rates varied from 264 pmp in Turkey to 15 pmp in
Ukraine. The mean age of patients starting RRT in 2008
ranged from 69 years in Dutch-speaking Belgium to
44 years in Ukraine. The highest prevalence of RRT for
ESRD was reported by Portugal (1408 pmp) and the low-
est by Ukraine (89 pmp). The prevalence of haemodialysis
on 31 December 2008 ranged from 66 pmp (Ukraine) to
875 pmp (Portugal) and the prevalence of peritoneal dialy-
sis from 8 pmp (Montenegro) to 115 pmp (Denmark). In
Norway, 70% of the patients on RRT on 31 December
2008 were living with a functioning graft (572 pmp). In
2008, the number of transplants performed pmp was high-
est in Spain (Catalonia) (64 pmp), whereas the highest
transplant rates with living-donor kidneys were reported
from the Netherlands (25 pmp) and Norway (21 pmp).
In the cohort 1999–2003, the unadjusted 1-, 2- and 5-year
survival of patients on RRT was 80.8% (95% CI: 80.6–
81.0), 69.1% (95% CI: 68.9–69.3) and 46.1% (95% CI:
45.9–46.3), respectively.
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Introduction
This summary of the 2008 ERA–EDTA Registry Report
includes the data on renal replacement therapy (RRT) from
55 national and regional registries in 30 countries in Eur-
ope and bordering the Mediterranean Sea (Figure 1). The
renal registries provided datasets with individual patient
data (36 registries) or in aggregated form (19 registries).
The data from all registries were used to present incidence
and prevalence of RRT data as well as transplant rates. Sur-
vival analyses used the data from countries and regions
that provided individual patient records. More detailed
data than those presented in this paper can be found in
the 2008 ERA–EDTA Registry Report [1] which is avail-
able at www.era-edta-reg.org.
Incidence of RRT for ESRD across Europe
Incidence is the number of new cases of a condition during a
specific period of time which, in this annual report, is a year
(2008). In 2008, the overall incidence rate of RRT for end-
stage renal disease (ESRD) among all registries reporting
to the ERA–EDTA Registry was 122 per million population
(pmp).Figure2showsthatthe highestincidenceratesatDay
1 were reported by Turkey (264 pmp), Portugal (232 pmp)
and Greece (199 pmp), whereas incidence rates below
100 pmp where reported by Ukraine (15 pmp), Monte-
negro(30pmp),Russia(37pmp),Estonia(66pmp),Iceland
(73 pmp), Latvia (95 pmp), Finland (95 pmp), Romania
(96 pmp) and Spain (Castile-La Mancha) (98 pmp). The
incidence rate of RRT for diabetic ESRD was highest in
Turkey (80 pmp), Israel (77 pmp) and Slovakia (71 pmp),
while the registries of Iceland, Romania, Ukraine, Monte-
negro, Russia, Estonia and Latvia reported incidence rates
forESRD duetodiabetes mellitusbelow20pmp(Figure2).
Table 1 shows the incidence rate of RRT over the period
2004–08 for countries and regions providing individual pa-
tient data, adjusted for age and gender distribution.
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data were available for 14 registries of 11 countries includ-
ing those of Austria, Denmark, Finland, Greece, Iceland,
Norway, Romania, Spain (Andalusia), Spain (Basque
country), Spain (Catalonia), Spain (Valencian region),
Sweden, the Netherlands and the UK (Scotland). As num-
bers of children starting RRTwere low we present averages
for 2007-2008 (Table 2). For an overview of paediatric
RRT data collected by the ESPN/ERA–EDTA Registry,
please visit www.espn-reg.org.
Figure 3 shows that the mean age of patients starting
RRT in 2008 ranged from 44 years in Ukraine to 69 years
in Dutch-speaking Belgium.
The incidence of the different treatment modalities was
measured as number of patients pmp on treatment modality
at Day 91 of RRT (Table 3). Whereas incidence rates of
haemodialysis were highest in Greece (160 pmp), Israel
(157 pmp), and in Dutch- and French-speaking Belgium
(150 pmp and 153 pmp respectively), the highest inci-
dence rates for peritoneal dialysis were reported from
Sweden (37 pmp), Denmark (34 pmp) and Finland and
Iceland (both 28 pmp). The highest incidence rates of
p a t i e n t sl i v i n go naf u n c t i o n i n gg r a f ta tD a y9 1o f
RRT were seen in Norway (15 pmp) and the Netherlands
(11 pmp).
Prevalence of RRT for ESRD across Europe
Prevalence is the number of people in a given population
with a particular disease at a given time, in this annual re-
port at December 31, 2008. The overall prevalence among
all registries reporting to the ERA–EDTA Registry was
644 pmp. Figure 4 shows that the prevalence of RRT
pmp at 31 December 2008 was highest in Portugal (1408
pmp), Belgium (French-speaking) (1153 pmp) and Spain
(Catalonia) (1124 pmp). The lowest prevalence was re-
ported by Ukraine (89 pmp) and Russia (165 pmp). Table 4
shows the overall prevalence of RRT, adjusted for age and
gender distribution.
Only a limited number of registries provided complete
data for prevalent patients in the age group 0-19 years
in 2008, including those of Austria, Denmark, Finland,
Greece, Iceland, Norway, Romania, Spain (Andalusia),
Spain (Basque country), Spain (Catalonia), Spain (Valen-
cian region), Sweden, the Netherlands and the UK
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Fig. 1. Incidence of RRT per million population (pmp) at Day 1, 2008 B&H, Bosnia–Herzegovina; FYROM, Former Yugoslav Republic of Macedonia.
2 V.S. Stel et al.(Scotland). The prevalence for age group 0–19 years is
presented in Table 5.
The mean age of patients on RRTon 31 December 2008
rangedfrom44years(Ukraine)to64years(Dutch-speaking
Belgium and Italy) for registries providing data on both
dialysis and transplant patients (Figure 5).
The prevalence of haemodialysis on 31 December 2008
was highest in Portugal (875 pmp), Greece (753 pmp) and
Italy(16of20regions)(739pmp),andthelowestinUkraine
(66 pmp), Russia (118 pmp) and Iceland (154 pmp)
(Table 6). The prevalence of peritoneal dialysis was high-
est in Denmark (115 pmp), the UK, Wales (102 pmp)
and Sweden (92 pmp), whereas the lowest prevalence
of this treatment was reported in Montenegro (8 pmp),
Ukraine (11 pmp) and Russia (12 pmp). In Norway,
70% of the patients on RRTwere living with a functioning
graft (572 pmp).
Renal transplants performed in 2008
Table7showsthat thehighesttransplant rateswerereported
from Spain (Catalonia) (64 pmp), Norway (58 pmp) and
Spain (Basque country) (55 pmp). Countries with the
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Fig. 2. Incidence of RRT per million population (pmp) at Day 1 in 2008, for all patients and for patients with diabetes mellitus as primary renal disease,
unadjusted. Figures include data from renal registries providing individual patient data (left figure) and aggregated data (right figure). Data of Tunisia
are based on Day 91 of RRT.
The 2008 ERA–EDTA Registry Annual Report 3highest transplant rates with living-donor kidneys in-
cluded the Netherlands (25 pmp), Norway (21 pmp) and
Montenegro (19 pmp).
Patient and graft survival
For survival analysis data was used from 19 registries in 12
countries that provided individual patient records for the
period 1999–2003 [i.e. Austria, Belgium (Dutch-speaking),
Belgium (French-speaking), Denmark, Finland, Greece,
Iceland, Italy (Calabria), Norway, Spain (Andalusia), Spain
(Asturias), Spain (Basque country), Spain (Cantabria),
Spain (Catalonia), Spain (Valencian region), Sweden, the
Netherlands, the UK (England/Wales) and the UK
(Scotland)]. Three Spanish regions [i.e. Spain (Castile
and Leon), Spain (Castile-La Mancha) and Spain
(Extremadura)] were also included in the analyses based
on cohort 2002–06 because for these registries, complete
data were available from 2002. The data are presented for
all countries and regions together (Table 8 and Figures 6,
7 and 8). Comparisons of survival by treatment modality
were all adjusted for fixed values of age, gender and dis-
tribution of PRD. Similar adjustments have been applied
to survival comparisons by PRD (for fixed values and
further methodology, consult the Appendix section).
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Table 1. Incidence of RRT over the period 2004–08 per million
population (pmp) at Day 1, adjusted for age and gender distribution
Country/regions
providing individual
patient data
2004 2005 2006 2007 2008
pmp pmp pmp pmp pmp
Austria 164 155 161 155 149
Belgium
Dutch-speaking 172 172 178 174 173
French-speaking 191 181 191 190 194
Denmark 138 126 124 149 127
Finland 98 96 86 90 92
Greece 186 181 182 174 180
Iceland 90 85 84 94 89
Italy, Calabria 147 136 132 144 150
Norway 107 106 107 120 119
Spain
Andalusia 144 147 145 132 136
Asturias 137 104 109 109 107
Basque country 121 112 101 105 97
Cantabria 142 151 118 100 106
Catalonia 140 149 134 142 135
Castile and Leon 105 98 104 103 102
Castile-La Mancha 109 121 107 99 98
Valencian region 166 147 153 145 136
Sweden 119 116 124 123 116
The Netherlands 115 115 120 122 125
UK
England 91 111 115 110 110
Scotland 117 126 116 114 106
Wales 118 128 131 136 106
All countries 126 131 132 130 128
Table 2. Incidence of RRT over the period 2007-08 per million age-
related population (pmarp) per year at Day 1, by age group, unadjusted
Cohort
0–19 0–45 –91 0 –14 15–19
pmarp pmarp pmarp pmarp pmarp
2007–08 9.3 7.1 4.1 9.2 15.7
4 V.S. Stel et al.Appendix
Statistical methods
Table 8
The data presented include the survival of incident patients
on RRTand of patients receiving a first transplant between
1999 and 2003 or between 2002 and 2006 with their 95%
confidence intervals. Patients were followed-up until 31
December 2008. Statistical analysis of unadjusted survival
was performed by the Kaplan–Meier method.
For the analysis of patient survival on RRT, the day at the
start of RRTwas taken as the starting point, and the event
studied was death. Censored observations were recovery of
renal function, loss to follow-up and end of follow-up time.
For the analysis of patient survival on dialysis, the first
day on dialysis was the starting point, the event was
death, and reasons for censoring were recovery of renal
function, loss to follow-up, end of follow-up time and
renal transplantation.
For the analysis of patient and graft survival after trans-
plantation, the date of the first renal transplantation was
defined as the first day of follow-up.
For the patient survival after transplantation, the event
studied was death, and for the graft survival, the events
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Fig. 3. Mean age (years) of patients starting RRT in 2008. Figures include data from renal registries providing individual patient data (left figure) and
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The 2008 ERA–EDTA Registry Annual Report 5were graft failure and death. Reasons for censoring were
loss to follow-up and end of follow-up time.
Figure 6
For the analyses of patient survival on dialysis, the starting
point was Day 91 on dialysis. Analyses were adjusted for
the fixed values of age (60 years), gender (60% men), and
primary renal disease (20% diabetes mellitus, 17% hyper-
tension/renal vascular disease, 15% glomerulonephritis
and 48% other causes).
For the analyses of patient survival after transplantation,
the starting point was the time of the first transplant. Ana-
lyses were adjusted for the fixed values of age (45 years),
gender (60% men), and primary renal disease (10% dia-
betes mellitus, 8% hypertension/renal vascular disease,
28% glomerulonephritis and 54% other causes).
Figures 7 and 8
For the analyses presented in each figure, the starting point
was Day 91 on dialysis. Analyses were adjusted for the
fixed values of age (60 years) and gender (60% men).
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Table 3. Incidence of RRT per million population (pmp) at Day 91 in 2008, by treatment modality, unadjusted
Country/regions
providing individual
patient data
All HD PD Tx Unkn/missing
Country/regions
providing aggregated data
All HD PD Tx Unkn/missing
pmp pmp pmp pmp pmp pmp pmp pmp pmp pmp
Austria 134 115 14 5 0 Bosnia-Herzegovina 102 92 5 0 5
Belgium Croatia 134 121 13 1 0
Dutch-speaking 172 150 20 2 0 Czech Republic 150 141 9 0
French-speaking 172 153 14 4 1 Estonia 63 39 21 3 0
Denmark 117 79 34 4 0 France (20 of 26 regions) 130 109 15 5 2
Finland 94 65 28 1 0 FYR of Macedonia 108 102 3 3 0
France (16 of 26 regions) 123 102 16 6 0 Israel 174 157 14 3 0
Greece 177 160 17 1 0 Italy (16 of 20 regions) 145 127 18 0
Iceland 69 38 28 3 0 Latvia 87 72 15 1 0
Italy (13 of 20 regions) 142 115 22 5 0 Montenegro 29 22 0 6 0
Norway 106 72 19 15 0 Poland
Romania 90 72 16 2 0 Portugal
Spain Russia 34 29 5 0 0
Andalusia 120 102 14 3 0 Slovakia 157 147 11 0
Asturias 124 98 20 5 1 Slovenia 112 110 2 0 0
Basque country 98 76 20 1 0 Spain (18 of 19 regions)
Cantabria 111 89 17 5 0 Tunisia 135 128 8 0
Castile and Leon 122 99 23 0 0 Turkey
Castile-La Mancha 101 87 12 2 0 Ukraine 15 12 3 0 0
Catalonia 129 107 15 7 0
Extremadura 121 99 22 0 1
Valencian region 129 118 10 2 0
Sweden 106 64 37 5 0
The Netherlands 109 74 24 11 0
UK
All countries 100 73 20 6 1
England 100 72 20 7 1
Northern Ireland 100 81 18 2 0
Scotland 98 75 18 5 0
Wales 102 78 21 3 0
Categories may not add up because of rounding off. When cells are left empty, (complete) data are unavailable.
HD, haemodialysis; PD, peritoneal dialysis; Tx, transplantation; Unkn, unknown.
6 V.S. Stel et al.11
15
53
45
93
228
276
98
95
83
154
188
131
163
140
138
157
98
89
165
332
403
467
538
569
689
690
696
706
750
761
839
904
968
994
1059
1408
595
0 500 1000 1500
Ukraine
Russia
Montenegro
Latvia
Estonia
Czech Republic
Slovakia
Israel
Poland
Bosnia-Herzegovina
FYR of Macedonia
Tunisia
Turkey
Italy (16 of 20 regions)
Croatia
Slovenia
Spain (18 of 19 regions)
France (20 of 26 regions)
Portugal
All countries
36
41
202
108
109
121
94
106
127
101
94
147
162
143
113
202
139
124
125
129
190
150
98
117
200
143
190
124
422
520
768
781
786
810
816
821
832
844
845
852
873
896
910
951
969
971
980
1028
1033
1039
1050
1081
1115
1124
1153
881
0 500 1000 1500
Romania
Iceland
Finland
United Kingdom, England
United Kingdom, All countries
United Kingdom, Northern Ireland
Norway
United Kingdom, Scotland
United Kingdom, Wales
Spain, Cantabria
The Netherlands
Denmark
Sweden
Spain, Castile-La Mancha
Spain, Extremadura
Austria
Spain, Castile and Leon
Spain, Andalusia
France (16 of 26 regions)
Italy (13 of 20 regions)
Greece
Spain, Asturias
Spain, Basque country
Spain, Valencian region
Belgium, Dutch-speaking
Spain, Catalonia
Belgium, French-speaking
All countries
All 
Primary renal disease diabetes mellitus 
Prevalence pmp Prevalence pmp
Fig. 4. Prevalence of RRT per million population (pmp) on 31 December 2008, for all patients and for patients with diabetes mellitus as primary renal
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The 2008 ERA–EDTA Registry Annual Report 7Table 4. Prevalence of RRTon December 31 over the period 2004-08 per
million population (pmp), adjusted for age and gender distribution
Country/regions
providing individual
patient data
2004 2005 2006 2007 2008
pmp pmp pmp pmp pmp
Austria 860 887 910 929 976
Belgium
Dutch-speaking 916 950 983 1009 1042
French-speaking 1021 1054 1101 1136 1179
Denmark 777 786 794 831 848
Finland 682 704 711 723 740
Greece 886 910 923 939 953
Iceland 546 537 538 575 585
Italy, Calabria 946 948 953 968 969
Norway 751 771 791 820 852
Spain
Andalusia 1002 1034 1031 1015 1034
Asturias 838 854 867 873 888
Basque country 890 926 937 953 965
Catalonia 1085 1076 1077 1113 1135
Cantabria 796 796 791 780 794
Castile-La Mancha 874 907 913 912 914
Castile and Leon 806 820 827 821 840
Valencian region 1103 1085 1091 1094 1084
Sweden 793 804 827 841 847
The Netherlands 734 760 794 818 854
UK
England 557 708 734 769 797
Scotland 739 765 784 808 817
Wales 692 715 740 814 813
All countries 760 826 846 867 889
Table 5. Prevalence of RRT per million age-related population (pmarp)
on 31 December 2008, by age group, unadjusted
Year
0–19 0–45 –91 0 –14 15–19
pmarp pmarp pmarp pmarp pmarp
2008 56 17 36 58 107
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The 2008 ERA–EDTA Registry Annual Report 9Table 6. Prevalence of RRT per million population (pmp) on 31 December 2008, by treatment modality, unadjusted
Country/regions
providing individual
patient data
All HD PD Tx Unkn/missing
Country/regions
providing aggregated data
All HD PD Tx Unkn/missing
pmp pmp pmp pmp pmp pmp pmp pmp pmp pmp
Austria 951 443 43 465 0 Bosnia-Herzegovina 696 615 31 43 7
Belgium Croatia 904 618 55 230 0
Dutch-speaking 1115 590 66 460 0 Czech Republic 538 494 44 0
French-speaking 1153 633 54 465 1 Estonia 467 156 52 259 0
Denmark 852 380 115 352 4 France (20 of 26 regions) 1059 530 43 484 2
Finland 768 250 69 450 0 FYR of Macedonia 706 621 14 71 0
France (16 of 26 regions) 980 501 40 439 1 Israel 689 645 44 0
Greece 1033 753 68 212 0 Italy (16 of 20 regions) 839 739 78 22
Iceland 520 154 44 321 0 Latvia 403 156 50 198 0
Italy (13 of 20 regions) 1028 687 88 253 0 Montenegro 332 290 8 34 0
Norway 816 203 40 572 0 Poland 690 407 29 254 0
Romania 422 325 68 29 0 Portugal 1408 875 48 485 0
Spain Russia 165 118 12 35 0
Andalusia 971 475 39 456 0 Slovakia 569 532 37 0
Asturias 1039 363 53 556 67 Slovenia 968 661 52 255 0
Basque country 1050 353 89 608 0 Spain (18 of 19 regions) 994 468 49 477 0
Cantabria 844 331 58 454 0 Tunisia 750 734 16 0
Castile and Leon 969 432 56 476 5 Turkey 761 569 82 111 0
Castile-La Mancha 896 395 36 466 0 Ukraine 89 66 11 12 0
Catalonia 1124 518 41 565 0
Extremadura 910 455 55 400 1
Valencian region 1081 608 41 430 3
Sweden 873 296 92 484 0
The Netherlands 845 293 74 478 0
UK
All countries 786 357 75 329 25
England 781 355 75 324 27
Northern Ireland 810 412 58 339 1
Scotland 821 354 65 401 1
Wales 832 373 102 317 41
Categories may not add up because of rounding off. When cells are left empty, (complete) data are unavailable.
HD, haemodialysis; PD, peritoneal dialysis; Tx, transplantation; Unkn, unknown.
10 V.S. Stel et al.Table 7. Renal transplants performed per million population (pmp) in 2008, by donor type, unadjusted
Country/regions
providing individual
patient data
All
Living
donor
Deceased
donor
Unknown
type donor Country/regions
providing aggregated data
All
Living
donor
Deceased
donor
Unknown
type donor
pmp pmp pmp pmp pmp pmp pmp pmp
Austria 40 7 33 0 Bosnia-Herzegovina 7 5 3 0
Belgium Croatia 35 4 26 6
Dutch-speaking 38 2 35 1 Czech Republic 32 3 29 0
French-speaking 33 2 29 2 Estonia 43 2 40 0
Denmark 36 14 23 0 France (20 of 26 regions) 45 4 42 0
Finland 28 2 26 0 FYR of Macedonia 4 4 0 0
France (16 of 26 regions) 44 2 38 3 Israel 33 8 13 12
Greece 24 6 17 0 Italy (16 of 20 regions) 35 3 32 0
Iceland 16 16 0 0 Latvia 22 0 21 0
Italy (13 of 20 regions) 20 1 3 16 Montenegro 26 19 6 0
Norway 58 21 38 0 Poland 22 1 22 0
Romania 7 7 Portugal 49 5 45 0
Spain Russia 6 1 5 0
Andalusia 45 45 Slovakia
Asturias 37 0 37 0 Slovenia 26 0 26 0
Basque country 55 0 55 0 Spain (18 of 19 regions) 48 3 45 0
Cantabria 50 3 46 0 Tunisia 12 10 3 0
Castile and Leon 37 0 37 0 Turkey 19 13 5 0
Castile-La Mancha 50 1 46 2 Ukraine 2 1 0 0
Catalonia 64 11 53 0
Extremadura 36 0 31 5
Valencian region 40 0 38 1
Sweden 46 15 31 0
The Netherlands 47 25 22 1
UK
All countries 41 15 25 0
England 42 16 26 0
Northern Ireland 23 5 18 0
Scotland 41 13 28 0
Wales 33 10 24 0
Categories may not add up because of rounding off. When cells are left empty, (complete) data are unavailable.
Table 8. One-, 2- and 5-years survival probabilities, unadjusted
Cohort 1999–2003 Cohort 2002–06
1-year 2-year 5-year 1-year 2-year
Patient survival on RRT 80.8 (80.6–81.0) 69.1 (68.9–69.3) 46.1 (45.9–46.3) 81.5 (81.3–81.7) 70.3 (70.1–70.5)
Patient survival on dialysis 80.3 (80.0–80.5) 67.2 (67.0–67.5) 38.3 (38.1–38.4) 80.8 (80.6–81.0) 68.4 (68.2–68.6)
Patient survival after first transplant
(deceased donor)
95.5 (95.1–95.8) 93.6 (93.1–94.0) 86.6 (86.1–87.1) 95.6 (95.3–95.9) 93.7 (93.3–94.1)
Patient survival after first transplant
(living donor)
97.6 (97.0–98.1) 96.8 (96.1–97.3) 94.1 (93.2–94.8) 97.9 (97.4–98.3) 97.1 (96.5–97.6)
Graft survival after first transplant
(deceased donor)
90.0 (89.5–90.5) 87.0 (86.5–87.6) 77.6 (77.0–78.1) 90.0 (89.5–90.4) 87.2 (86.7–87.7)
Graft survival after first transplant
(living donor)
94.4 (93.5–95.1) 92.6 (91.7–93.4) 86.2 (85.1–87.2) 94.5 (93.7–95.1) 92.8 (92.0–93.5)
For analysis methods, see the Appendix section.
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Fig. 6. Survival of incident dialysis patients and of patients receiving a
first transplant between 1999 and 2003, by treatment modality, adjusted
for age, gender and primary renal disease.
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Fig. 7. Survival of incident haemodialysis patients in 1999–2003, from
Day 91, by primary renal disease, adjusted for age and gender.
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Fig. 8. Survival of incident peritoneal dialysis patients in 1999–2003,
from Day 91, by primary renal disease, adjusted for age and gender.
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